Carrier mediated protein and peptide stabilization

Tiwari, Anjali; Gajbhiye, Virendra; Sharma, Rajeev; Jain, Narendra Kumar

doi:10.3109/10717544.2010.509359

Cited by 29 publications

(13 citation statements)

References 115 publications

(94 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mechanism of interaction, involving hydrogen bonds and hydrophobic interaction, has long been studied aimed at the elucidation of structure-activity relationship (Rawel & Rohn, 2010;Spencer et al, 1988;Tiwari, Gajbhiye, Sharma, & Jain, 2010). In general, larger polyphenols have been reported to have a higher ability to bind proteins than smaller ones (Hagerman, Rice, & Ritchard, 1998).…”

Section: Protein-polyphenol Interactionmentioning

confidence: 99%

Structural aspects of legume proteins and nutraceutical properties

Carbonaro

Maselli

Nucara

2015

Food Research International

163

120

View full text Add to dashboard Cite

Section: Protein-polyphenol Interactionmentioning

confidence: 99%

Structural aspects of legume proteins and nutraceutical properties

Carbonaro

Maselli

Nucara

2015

Food Research International

163

120

View full text Add to dashboard Cite

“…Furthermore, the progress in biotechnological engineering has led to the evolvement of new biological-based therapeutics and vaccines that are usually characterized by limited ability to cross cell membranes accompanied by poor in vivo performance due to degradation in the gastrointestinal tract (GIT) (Boyd, 2008;Li et al, 2012). Different strategies that include encapsulating therapeutic agents or vaccines into nano-colloidal delivery systems (polymeric or lipid-based nanoparticles, nanoemulsions, nanostructured lipid carriers, mixed micelles and vesicular structures) have been adopted by researchers to cope with impediments associated with delivering these challenging agents to specific target tissues (Malik et al, 2007;Tiwari et al, 2010;Li et al, 2012;Gupta et al, 2013;Demetzos & Pippa, 2014). Among different classes of colloidal systems, vesicular carriers have gained particular attention in delivering poorly soluble drugs and proteins/ peptides (Torchilin, 2005).…”

Section: Introductionmentioning

confidence: 99%

Bile salts-containing vesicles: promising pharmaceutical carriers for oral delivery of poorly water-soluble drugs and peptide/protein-based therapeutics or vaccines

Aburahma¹

2014

Drug Delivery

103

View full text Add to dashboard Cite

Most of the new drugs, biological therapeutics (proteins/peptides) and vaccines have poor performance after oral administration due to poor solubility or degradation in the gastrointestinal tract (GIT). Though, vesicular carriers exemplified by liposomes or niosomes can protect the entrapped agent to a certain extent from degradation. Nevertheless, the harsh GIT environment exemplified by low pH, presence of bile salts and enzymes limits their capabilities by destabilizing them. In response to that, more resistant bile salts-containing vesicles (BS-vesicles) were developed by inclusion of bile salts into lipid bilayers constructs. The effectiveness of orally administrated BS-vesicles in improving the performance of vesicles has been demonstrated in researches. Yet, these attempts did not gain considerable attention. This is the first review that provides a comprehensive overview of utilizing BS-vesicles as a promising pharmaceutical carrier with a special focus on their successful applications in oral delivery of therapeutic macromolecules and vaccines. Insights on the possible mechanisms by which BSvesicles improve the oral bioavailability of the encapsulated drug or immunological response of entrapped vaccine are explained. In addition, methods adopted to prepare and characterize BSvesicles are described. Finally, the gap in the scientific researches tackling BS-vesicles that needs to be addressed is highlighted.

show abstract

“…The success of any therapeutic protein drug delivery depends not only upon improving its bioactivity, but also on improving its bioavailability in the human body (Tiwari et al, 2010;Shegokar and Müller, 2010). Although several drug delivery strategies have been focused on systems to improve bioactivity and bioavailability, none have proved fully satisfactory due to limitations posed by the sensitivity of protein structures in biological environments.…”

Section: Introductionmentioning

confidence: 99%